Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRETIS-TNK: Intra-arterial Tenecteplase for Ischemic Stroke
NCT04202458Phase 2Completed
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Dec 2019
- Primary completion
- Aug 2021
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tenecteplase in ischemic stroke, sponsored by General Hospital of the Northern Theater Command. Primary endpoint: Proportion of sufficient recanalization (mTICI 2b-3). Started Dec 2019; status: completed.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04202458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04202458.